SORT BY

FILTER BY

also on other fortune lists

company facts

f500 stats

Fortune 500

Courtesy of Celgene

224

Celgene

CELG

The biopharmaceutical company is the maker of Thalomid and various other drugs that treat multimple myeloma, inflammatory diseases, and various forms of cancer.

Looking for leads, investment insights, or competitive intelligence?

CEO

Mark J. Alles

CEO Title

Chairman & Chief Executive Officer

Sector

Health Care

Industry

Pharmaceuticals

HQ Location

Summit, N.J.

Years on Fortune 500 List

7

Employees

7,467

Key Financials (Last Fiscal Year)
$ millions% change
Revenues ($M)$13,00315.8%
Profits ($M)$2,940.047.1%
Assets ($M)$30,141
Total Stockholder Equity ($M)$6,921
Market Value — as of March 29, 2018 ($M)$67,102
Profit Ratios
Profit as % of Revenues22.6%
Profits as % of Assets9.8%
Profits as % of Stockholder Equity42.5%
Earnings Per Share (Last Fiscal Year)
Earnings Per Share ($)3.64
EPS % Change (from 2016)46.2%
EPS % Change (5 year annual rate)17.1%
EPS % Change (10 year annual rate)29.7%
Total Return
Total Return to Investors (2017)-9.8%
Total Return to Investors (5 year, annualized)21.6%
Total Return to Investors (10 year, annualized)16.3%
STOCK QUOTE
()0.00 0.00 (0)
  • Previous Close:
  • Market Cap: NaNB
  • Next Earnings Date:
  • High:
  • Low:
  • 52 Week High:
  • 52 Week Low:
  • 52 Week Change %: 0.00
  • P/E Ratio: n/a
  • EPS:
  • Dividend Yield: n/a

News about Celgene

Russian Drugmaker Granted License to Produce Celgene Copycat

Russian drugmaker Nativa got a compulsory license to produce a cheaper version of Celgene's Revlimid.

Read More →
The FDA Is Naming and Shaming Companies Accused of Blocking Cheap Generic Drugs

Celgene and Novartis are among the companies accused of thwarting generic drugs.

Read More →
Why Analysts Are Calling Celgene's $9 Billion Juno Acquisition a 'Smart' Biotech Deal

Juno's stock is up a staggering 76% since rumors of the Celgene deal emerged last week.

Read More →
Celgene Is Paying $9 Billion for Juno Therapeutics in Blockbuster Cancer Drug Deal

With Juno, Celgene will gain research into a novel class of therapies known as CAR-T.

Read More →
This 31-Year-Old CEO Is Snapping Up Drug Industry Veterans Left and Right

Former Celgene president Jackie Fouse is joining the unconventional Roivant crew.

Read More →